

# UK PREvention of Cancer by Intervention with SElenium

<b>Submission date</b> 18/05/2001	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 18/05/2001	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 02/02/2012	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Margaret Rayman

**Contact details**  
Faculty of Health and Medical Sciences  
University of Surrey  
Guildford  
United Kingdom  
GU2 5XH  
+44 (0)1483 686447  
M.Rayman@surrey.ac.uk

## Additional identifiers

**ClinicalTrials.gov (NCT)**  
NCT00022165

## Study information

**Scientific Title**  
UK PREvention of Cancer by Intervention with SElenium: a pilot randomised controlled feasibility study

## Acronym

UK PRECISE Pilot Study

## Study objectives

The PRECISE trial aims to show not only whether selenium has a protective effect against cancer, but also how much selenium is needed to have this effect and which people will benefit most.

Added as of 27/03/2009: Please note that the main trial never started due to lack of funding. The pilot study was successfully completed, and the pilot trial information was added to this record on 12/07/2010. All changes can be found below in the relevant section with the above update date.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Added 13/07/2010:

1. South Tees Research Ethics Committee approved on the 1st February 2000 (ref: 99/69)
2. Worcestershire Health Authority Local Research Ethics Committee approved on the 17th March 2000 (ref: LREC 74/99)
3. Norwich District Research Ethics Committee approved on the 9th December 1999 (ref: LREC 99 /141)
4. Great Yarmouth and Waveney LREC approved on the 22nd February 2000 (under reciprocal arrangements with Norwich District LREC)

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Study type(s)

Prevention

## Health condition(s) or problem(s) studied

Multiple cancer sites

## Interventions

Current information as of 12/07/2010:

Participants receive either a 100 µg, 200 µg, 300 µg selenium as selenium-enriched yeast supplement or a placebo yeast supplement every day for six months. Follow-up was for a minimum of six months (we had hoped this pilot would lead into the main trial phase).

Previous information at time of registration:

Participants receive either a 100 µg, 200 µg, 300 µg selenium supplement or a placebo every day.

## Intervention Type

Drug

## Phase

Not Specified

**Drug/device/biological/vaccine name(s)**

Selenium

**Primary outcome(s)**

Added 12/07/2010:

This was a feasibility study to show the ability to run the main trial.

**Key secondary outcome(s)**

Added 12/07/2010:

1. Mood (Profile of Mood States Bi-Polar Form [POMS-BI]), measured at baseline and 6 months
2. Quality of life (36-item Short Form Health Survey [SF-36]), measured at baseline and 6 months
3. Thyroid function (thyroid stimulating hormone [TSH], total and free T4 and T3), measured at baseline and six months

**Completion date**

31/12/2002

**Eligibility****Key inclusion criteria**

Volunteers aged 60 - 74 years old, either sex

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Senior

**Sex**

All

**Key exclusion criteria**

Added 12/07/2010:

1. Southwest Oncology Group (SWOG) grading scale performance status score greater than 1 or equivalent
2. Active liver or kidney disease (known abnormal liver or kidney function)
3. Prior diagnosis of cancer (excluding non-melanoma skin cancer)
4. Diagnosed human immunodeficiency virus (HIV) infection
5. Diminished mental capacity (subjects must be able to give informed consent to participate as defined by ethics committees)
6. Taking 50 µg/day or more of selenium supplements

**Date of first enrolment**

01/01/2000

**Date of final enrolment**

31/12/2002

## Locations

### Countries of recruitment

United Kingdom

England

### Study participating centre

**Faculty of Health and Medical Sciences**

Guildford

United Kingdom

GU2 5XH

## Sponsor information

### Organisation

Cancer Research UK (CRUK) (UK)

### ROR

<https://ror.org/054225q67>

## Funder(s)

### Funder type

Charity

### Funder Name

Cancer Research Campaign (UK) - funded a pilot trial for this study, completed in 2002

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

<b>Output type</b>	<b>Details</b>	<b>Date created</b>	<b>Date added</b>	<b>Peer reviewed?</b>	<b>Patient-facing?</b>
<a href="#">Results article</a>	selenium supplementation, mood and quality of life results	15/01/2006		Yes	No
<a href="#">Results article</a>	selenium supplementation and thyroid function results	01/02/2008		Yes	No
<a href="#">Results article</a>	high-selenium yeast on plasma lipids results	17/05/2011		Yes	No
<a href="#">Other publications</a>	supplementation with selenium does not affect total homocysteine concentration in the UK elderly population:	01/11/2008		Yes	No